Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Sales and Divestitures: 2022-2024

Historic Gains from Sales and Divestitures for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $267,779.

  • Axsome Therapeutics' Gains from Sales and Divestitures rose 19.48% to $295,835 in Q3 2025 from the same period last year, while for Sep 2025 it was $295,835, marking a year-over-year increase of 19.48%. This contributed to the annual value of $267,779 for FY2024, which is 37.73% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Gains from Sales and Divestitures of $267,779 as of FY2024, which was up 37.73% from $194,425 recorded in FY2023.
  • Axsome Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $267,779 during FY2024, with a 5-year trough of $81,639 in FY2022.
  • Over the past 3 years, Axsome Therapeutics' median Gains from Sales and Divestitures value was $194,425 (recorded in 2023), while the average stood at $181,281.
  • Data for Axsome Therapeutics' Gains from Sales and Divestitures shows a peak YoY spiked of 138.15% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $81,639 in 2022, then spiked by 138.15% to $194,425 in 2023, then soared by 37.73% to $267,779 in 2024.